Medical Bulletin 24/April/2023.

Published Date: 28 Apr 2023

Here are today's top medical stories:A new peptide-related to the calcitonin gene called atogepant may help prevent migraines in some challenging cases.

Read Full News

Latest News

Vasectomy Reversal More Cost-Effective Than IVF

Most couples younger than 40 years can achieve pregnancy within typical $30,000-$40,000 employer fertility benefits with reversal, new research indicates.

US Judge Rejects Bayer Bid to Block Johnson & Johnson Prostate Cancer Drug Claims

A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that ⁠its multibillion-dollar drug cuts the risk of...

This Test Could Predict Incontinence Risk After HoLEP

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

Smartphone App Helps Delay Ejaculation

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

US FDA Approves Lantheus' New Prostate Cancer Imaging Formulation

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Will a Smart Toilet Turn the Home Into a Diagnostic Center?

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Most couples younger than 40 years can achieve pregnancy within typical $30,000-$40,000 employer fertility benefits with reversal, new research indicates.

A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that ⁠its multibillion-dollar drug cuts the risk of...

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

News All Time

During the Accountable Care Meeting, CMS Officials were pressed on the topic of scanner fraud.

"We would appreciate it if you could give the matter more immediate attention," one ACO member said.

Nivolumab Plus Chemotherapy in First Line Approved for Bladder Cancer.

Combination decreased death risk by 22%.

King Charles III's Operation; COVID-19 Timeline Under Question; FDA Approvals Reach Record High.

The staff of MedPage Today has compiled health news and commentary from around the web.

Noninvasive Treatment Effective in Bladder Cancer That Is Not Muscle-Invasive.

An investigational intrusive solution produced a 79% complete response rate.

For Prostate Cancer at Intermediate Risk, SBRT Is Not Less Effective Than Conventional RT.

Similar results are obtained from treatment lasting one to two weeks as compared to therapy lasting up to seven and a half weeks.

The new first-line standard for advanced bladder cancer was produced by a landmark trial.

When compared to chemotherapy, enfortumab vedotin-pembrolizumab doubles OS and PFS.

Should Patients With Advanced Prostate Cancer Get Off the Active Surveillance Train?

Clearly defined rules are needed.

Even in those with HIV, a single dose of antibiotics was able to cure early syphilis.

In a randomized trial, one dosage showed no worse results than a triple-dose regimen.

Removing Cancer Survivors From Oncologic Treatment.

A new approach to care is required.

Cabazitaxel Lower-Dose Schedule Is Viable for Elderly Patients With mCRPC.

Neutropenia of grade three or above, with a twelve-fold reduction in neutropenic consequences.

AR-Pathway Inhibitor Switch for mCRPC is Superseded by Radionuclide Therapy.

With 177Lu-PSMA-617, the time to radiographic progression was doubled.

An RCT Supports HIF-2a Inhibition in Advanced RCC.

Belzutifan outperforms everolimus in the event of immunotherapy-TKI failure.

Finding New Routes to Improve Renal Cell Carcinoma Outcomes.

It is necessary to intervene at several stages of the cancer immunity cycle in order to build on recent successes.

CAR T-Cell Therapy for Renal Cell Carcinoma: "We're Not There Yet".

Possibility of standard of care following current therapies, but significant barriers still need to be overcome.

In severe cases of renal cell carcinoma, tyrosine kinase inhibitor activity is present.

Reactions to the "special medication" zanzalintinib in patients exposed and not exposed to cabozantinib.

Dietary inflammation is associated with the development of urologic cancers.

In health research, the relationship between dietary habits and cancer risks is still a major focus. The has been the subject of a recent meta-analysis.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

Mammo Responsibility Increases Screening; Opioids for Pain Related to Cancer? Ignored CRC Signs.

Participate and win cash vouchers

Get updates on the latest events happening around the world

2.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

3.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

4.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

5.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.

1.

The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy

2.

The Role of the Oncology Pharmacist: From Treatment to Trials and Beyond

3.

Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense

4.

New Hope for Rectal Cancer Patients: Breakthrough Drug Shows Promising Results

5.

Unveiling the Mystery of Echinocyte: A Closer Look at the Unique Red Blood Cell

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

2.

The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

5.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Medical Bulletin 24/April/2023.

Latest News

Vasectomy Reversal More Cost-Effective Than IVF

US Judge Rejects Bayer Bid to Block Johnson & Johnson Prostate Cancer Drug Claims

This Test Could Predict Incontinence Risk After HoLEP

Smartphone App Helps Delay Ejaculation

US FDA Approves Lantheus' New Prostate Cancer Imaging Formulation

Will a Smart Toilet Turn the Home Into a Diagnostic Center?

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

Datopotamab Deruxtecan Earns New Breast Cancer Indication

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

Datopotamab Deruxtecan Earns New Breast Cancer Indication

Latest News

News All Time

During the Accountable Care Meeting, CMS Officials were pressed on the topic of scanner fraud.

Nivolumab Plus Chemotherapy in First Line Approved for Bladder Cancer.

King Charles III's Operation; COVID-19 Timeline Under Question; FDA Approvals Reach Record High.

Noninvasive Treatment Effective in Bladder Cancer That Is Not Muscle-Invasive.

For Prostate Cancer at Intermediate Risk, SBRT Is Not Less Effective Than Conventional RT.

The new first-line standard for advanced bladder cancer was produced by a landmark trial.

Should Patients With Advanced Prostate Cancer Get Off the Active Surveillance Train?

Even in those with HIV, a single dose of antibiotics was able to cure early syphilis.

Removing Cancer Survivors From Oncologic Treatment.

Cabazitaxel Lower-Dose Schedule Is Viable for Elderly Patients With mCRPC.

AR-Pathway Inhibitor Switch for mCRPC is Superseded by Radionuclide Therapy.

An RCT Supports HIF-2a Inhibition in Advanced RCC.

Finding New Routes to Improve Renal Cell Carcinoma Outcomes.

CAR T-Cell Therapy for Renal Cell Carcinoma: "We're Not There Yet".

In severe cases of renal cell carcinoma, tyrosine kinase inhibitor activity is present.

Dietary inflammation is associated with the development of urologic cancers.

Recommended News For You

CDC Alerts on Dramatic Rise in Human Parvovirus B19

What Patients Hear From Us: 'Blah, Blah, Tumor, Blah, Blah, Cancer'

According to a study, male testicular cancer risk is linked to neurodevelopmental disorders.

Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.

Compared to previous estimates, a greater number of patients participate in cancer treatment trials.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

Mammo Responsibility Increases Screening; Opioids for Pain Related to Cancer? Ignored CRC Signs.

Recommended Articles For You

Understanding Macrocytosis: Causes, Symptoms, and Treatment Options

Unlocking the Mysteries of ICD 10 Code Normocytic Anemia

Unlocking the Mystery of Ovarian Cancer Staging

Undersanding Alemtuzumab: What You Need To Know About This Multiple Sclerosis Medication

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.